
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Pharmaceutical Executive offers a unique platform to engage with high level executives at pharmaceutical companies across multiple platforms






